.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,985,835

« Back to Dashboard

Details for Patent: 5,985,835

Title: Desmopressin for nocturia, incontinence and enuresis
Abstract:A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating nocturia, incontinence and enuresis with the high purity desmopressin produced therefrom.
Inventor(s): Larsson; Krister (Malmo, SE), Mellbrand; Thomas (Malmo, SE), Mornstam; Birgitta (Bunkeflostrand, SE), Roschester; Jan (Lund, SE), Skoldback; Jan-Ake (Malmo, SE), Asplund; Ragner (Strimsund, SE), N.o slashed.rgaard; Jens-Peter (Copenhagen, DK)
Assignee: Ferring B.V. (Hoofddorp, NL)
Filing Date:Jul 13, 1997
Application Number:08/924,459
Claims:1. A method for treating nocturia, incontinence and enuresis, comprising oral, nasal or intravenous administration of a dose of desmopressin effective to produce a physiological effect and having a purity of at least 98.5% with respect to adjoining matter other than water and acetic acid, said desmopressin having been produced in single batches of at least 50 g. said desmopressin produced by a process consisting of a final synthetic step, in which at least about 100 g. of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ. ID NO. 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, are dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

2. A single oral dose of desmopressin effective to produce a physiological effect for treatment of nocturia, incontinence and enuresis, said dose prepared from a desmopressin batch produced by a process for production of single batches of desmopressin having a weight of at least about 500 g. containing at least 98.5% by weight of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) in respect of adjoining matter other than water and acetic acid, consisting of a final synthetic step, in which at least about 1 kg. of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ. ID NO. 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, are dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

3. A single intranasal dose of desmopressin effective to produce a physiological effect for treatment of nocturia, incontinence and enuresis, said dose prepared from a desmopressin batch produced by a process for production of single batches of desmopressin having a weight of at least about 500 g. containing at least 98.5% by weight of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) in respect of adjoining matter other than water and acetic acid, consisting of a final synthetic step, in which at least about 1 kg. of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ. ID NO. 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, are dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

4. A single intravenous dose of desmopressin effective to produce a physiological effect for treatment of nocturia, incontinence and enuresis, said dose prepared from a desmopressin batch produced by a process for production of single batches of desmopressin having a weight of at least about 500 g. containing at least 98.5% by weight of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) in respect of adjoining matter other than water and acetic acid, consisting of a final synthetic step, in which at least about 1 kg. of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ. ID NO. 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, are dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

5. A single oral dose of desmopressin effective to produce a physiological effect for treatment of nocturia, incontinence and enuresis, said dose prepared from a single batch of desmopressin containing no less than 44 g of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) and no more than a total of 1.5% by weight of adjoining matter with respect to desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) other than water and acetic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc